Compound ID | 464
Class: Small molecule antibacterial agent
| Agent Type: | Synthetic; Small molecule; |
| Spectrum of activity: | Antimycobacterial |
| Mechanism of action: | DNA synthesis inhibitor. DNA minor groove binder |
| Target Pathogen: | Active against Mycobacterium tuberculosis |
| Institute where first reported: | George State University; CombinatoRx (Immtech Pharmaceuticals, USA) |
| Year first mentioned: | 2001 |
| Highest development stage: | Phase 1 (NCT00619346) |
| Development status: | Inactive |
| Reason dropped: | Was in clinical trials but not for bacterial infections. Phase I trials demonstrated safety in humans; currently in FDA clinical hold due to safety concerns |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/5480200 |
| Guide to Pharmacology: | pafuramidine |
| Citation: |